Researcher
Marc Ferrante
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Feb 2004 → Today
Projects
1 - 10 of 16
- Development of new strategies for value-based care in chronic inflammatory bowel diseases.From5 Dec 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Model informed Dosage optimization of Crizanlizumab for the management of Sickle Cell Disease in TanzaniaFrom17 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding and treating symptom burden in inflammatory bowel diseases: a psychological perspectiveFrom1 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The gut barrier as master regulator of microbiome-host interactions: exploring the structure and function of paracellular and transcellular transport in the large intestine.From1 Oct 2021 → TodayFunding: BOF - various, BOF - projects
- From drug development to registration: optimalization of flow processesFrom10 Feb 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Advanced 3D Complex Tissues BioAssembly Platform for Precision Disease Modeling, Drug Discovery and Regenerative Medicine (3D-BioBOT)From1 Jan 2021 → 31 Dec 2022Funding: BOF - scientific equipment program
- H2O Health Outcomes ObservatoryFrom1 Oct 2020 → TodayFunding: H2020 - Health, demographic change and wellbeing
- OrganID: Organ-derived complex 2D/3D cultures in human diseaseFrom1 Oct 2020 → TodayFunding: FWO Strategic Basic Research (SBO)
- LONG-TERM SEQUENTIAL USE OF BIOLOGIC THERAPIES IN INFLAMMATORY BOWEL DISEASE: HARMLESS OR HAZARDOUS?From1 Aug 2017 → 24 Sep 2021Funding: FWO fellowships
- Predicting response to treatment in patients with inflammatory bowel diseaseFrom1 Jan 2017 → 31 Dec 2022Funding: Foreign private sponsor - undefined
Publications
21 - 30 of 468
- Defining Comprehensive Disease Control for Use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations(2023)
Authors: Marc Ferrante
- Microbiome variance of the small bowel in Crohn's disease(2023)
Authors: Lucas Wauters, Matthias Ceulemans, João Guedelha Sabino, Marc Ferrante, Séverine Vermeire, Tim Vanuytsel, Jeroen Raes
Pages: 1626 - 1628 - Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis(2023)
Authors: Marc Ferrante, Patrick Augustijns
Pages: 695 - 697 - A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases(2023)
Authors: Wannee Kantasiripitak, Debby Thomas, Ilse Hoffman, Marc Ferrante, Séverine Vermeire, Karen van Hoeve, Erwin Dreesen
Pages: 896 - 908 - DEVELOPMENT OF A BELGIAN CORE SET OF QUALITY OF CARE MEASUREMENTS FOR PATIENTS WITH INFLAMMATORY BOWEL THROUGH A NATIONAL DELPHI PROCESS(2023)
Authors: Peter Bossuyt, Caroline Weltens, Marc Ferrante
Pages: S676 - S677 - MICROSCOPIC CROHN'S DISEASE ACTIVITY VARIES SIGNIFICANTLY IN PAIRED SAME-SEGMENT BOWEL BIOPSIES: MULTIPLE BIOPSIES ARE NEEDED TO ACCURATELY EVALUATE HISTOLOGICAL STATUS(2023)
Authors: Matthias Lenfant, Bram Verstockt, Marc Ferrante, Gert De Hertogh
Pages: S891 - S892 - BASELINE RNA AND MICROBIOTA SIGNATURES ARE ASSOCIATED WITH RESPONSE AND GENERAL DECREASE IN BACTEROIDES-2 ENTEROTYPE AFTER FMT IN UC(2023)
Authors: Sara Deleu, Sare Verstockt, Kaline Arnauts, Bram Verstockt, Marc Ferrante, Gwen Falony, Jeroen Raes
Pages: S919 - S920 - NO INCREASED POSTOPERATIVE RISK OF VENOUS THROMBOEMBOLISM OR OTHER COMPLICATIONS IN PATIENTS WITH ULCERATIVE COLITIS UNDERGOING COLECTOMY AFTER USE OF JAK INHIBITOR(2023)
Authors: Marc Ferrante, Bram Verstockt
Pages: S642 - S642 - AN IMBALANCE IN ACTIVE EOSINOPHILS, T HELPER 1, T HELPER 2 AND REGULATORY T CELLS CHARACTERISES FIBROSTRICTURING CROHN'S DISEASE(2023)
Authors: Bo-jun Ke, Jonathan Cremer, Gianluca Matteoli, Gert De Hertogh, Marc Ferrante, Christine Breynaert, Bram Verstockt
Pages: S122 - S122 - LARGE PORTION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES REPORT DIFFICULTIES WITH PSYCHOLOGICAL WELLBEING, EVEN IN ABSENCE OF DISEASE ACTIVITY(2023)
Authors: Matthias Lenfant, Anouk Teugels, Bram Verstockt, Ilse Van Diest, Marc Ferrante
Pages: S689 - S690
Patents
1 - 5 of 5
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE (Inventor)